Loading stock data…
JNJ
$237.00+4.84 (+2.08%)
After Hours$236.71-0.29 (-0.12%)· Last close Jun 9
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Johnson & Johnson in the Healthcare sector is trading at $237.00 with a market capitalization of $564.2B. Wall Street consensus targets $252.87 (23 analysts), implying a +6.7% move over the next 12 months. The stock is currently near its 52-week high of $251.71, remaining 12.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
UNHPFEABBV
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$237.00
Potential Downside
4.6%
Whystock Fair Value$226.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Buy
Mean target$252.87+6.7%
Range$155.00 – $285.00
Fundamentals
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative M...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$564.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
27.19
Beta
Defensive asset. Lower volatility than the S&P 500.
0.26
Div Yield
Strong income play. Yield provides a meaningful total return floor.
231.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.42%
Volume
Today's trading volume
8.19M
Recent News
Johnson And Johnson Buys Firefly Bio To Deepen Oncology Growth Story
Johnson & Johnson agreed to acquire Firefly Bio for $1 billion in a move to expand its oncology pipeline. The deal adds degrader-antibody conjugate technology focused on KRAS-driven cancers to Johnson & Johnson's research efforts. The acquisition is aimed at strengthening Johnson & Johnson's position in cancer therapeutics beyond its existing portfolio. For investors tracking NYSE:JNJ, this acquisition comes with the stock at a share price of $232.16 and multi-year returns that have been...
All 30 Dow Jones Stocks Ranked: Buy, Sell or Hold?
Nvidia, Visa and Microsoft lead the list of Wall Street's top Dow Jones stocks to buy now. Some other names might surprise you.
The Dividend Strategy That Beats the 4% Rule by $400,000 Over 20 Years on a $1 Million Portfolio
A 65-year-old retiree with $1 million who follows the standard 4% rule withdraws $40,000 in the first year, then increases that amount over time to keep pace with inflation. A dividend-focused alternative starts slightly lower, at about $38,000 in annual income from a 3.8% blended yield, but does not require selling shares. Over 20 years, ... The Dividend Strategy That Beats the 4% Rule by $400,000 Over 20 Years on a $1 Million Portfolio
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
JNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.